2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thromboembolism
8
Venous Thrombosis
6
Neoplasms
6
Pulmonary Embolism
5
Thromboembolism
3
Lung Neoplasms
3
Multiple Myeloma
2
Lymphoma
2
Colorectal Neoplasms
2
Vascular Diseases
1
Urogenital Neoplasms
1
Thrombosis
1
Thrombocytopenia
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Hemorrhage
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
87
fludarabine phosphate
86
Peripheral Blood Stem Cell Transplantation
71
Mycophenolic Acid
58
Tacrolimus
57
Busulfan
57
Whole-Body Irradiation
55
Antilymphocyte Serum
47
Cyclosporine
46
fludarabine
39
Methotrexate
38
Filgrastim
38
Melphalan
32
ruxolitinib
30
Cytarabine
30
Radiotherapy
27
Azacitidine
23
Etoposide
21
Methylprednisolone
20
Cord Blood Stem Cell Transplantation
18
Specimen Handling
15
Sirolimus
15
Granulocyte Colony-Stimulating Factor
15
Decitabine
15
Biopsy
15
Flow Cytometry
14
Cyclosporins
14
Alemtuzumab
14
thymoglobulin
13
venetoclax
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Tinzaparin
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled